2014 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/10/14rogen has been Granted Orphan Drug Designation from the US FDA for its Innovative Treatment of UTUC
Urogen Pharma, a clinical stage specialty pharmaceutical company focused on treatment of urological diseases, announced today that MitoGel, a sustained release formulation of Mitomcin C, has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of Urinary Upper Tract Urothelial Carcinoma (UTUC).The novel sustained-release chemotherapy formulation is a non-surgical alternative to current standard treatment involving kidney removal, and sometimes ev... 
Printer Friendly Version
11/10/14UroGen is recruiting clinical centers for the OLYMPUS trial for UTUC patients
UroGen Pharma is planning to start the OLYMPUS trial during 2016 and is looking for centers in US and Europe. The study will evaluate  the feasibility, safety, durability and ablative effect of MMC Mixed With TCGel in patients with Upper Tract Urothelial Cancer UTUC. TheraCoat is planning to recruit an estimation of 80 patients.Investigators interested in participating, please contact Dr Michal Jeshurun at: michalj@urogen.com... 
Printer Friendly Version
10/10/14UroGen presented its Interstitial Cystitis safety and feasibility pilot study results during ICS 2014, Brazil
Dr Koby Stav from the Neurourology Division, Department of Urology, Assaf Harofeh Medical Center, presented the results of the study named “Safety and feasibility of intravesical instillation of botulinum toxin A in a novel hydrogel-based slow release delivery system in PBS/IC patients: A pilot study”.Conclusions of this study showed that intravesical instillation of TCGel+BTX was:Well toleratedAppears generally safeAssociated with apparent sustained reduction of PBS/IC symptoms for ... 
Printer Friendly Version